Arbutus Biopharma

398 articles with Arbutus Biopharma

• Arbutus Biopharma Appoints Tram Tran, M.D. to its Board of Directors

  11/11/2021

  Arbutus Biopharma Corporation today announced that Tram Tran, M.D. has been appointed to the Arbutus Board of Directors

• Arbutus to Participate at Jefferies London Healthcare Conference

  11/10/2021

  Arbutus Biopharma Corporation today announced that the Company will participate in a virtual fireside chat at the Jefferies London Healthcare Conference.

• Arbutus Announces New Data on AB-729 in Late Breaker Poster Presentation at AASLD - The Liver Meeting®

  11/10/2021

  Arbutus Biopharma Corporation today announced new AB-729 safety and efficacy data, as well as long-term data from HBV patients following discontinuation of treatment with AB-729. .

• Arbutus Reports Third Quarter 2021 Financial Results and Provides Corporate Update

  11/4/2021

  Arbutus Biopharma Corporation today reports its third quarter 2021 financial results and provides a corporate update.

• Arbutus Announces Late-Breaker Abstract Accepted for Presentation at AASLD - The Liver Meeting® 2021

  11/1/2021

  Arbutus Biopharma Corporation announced that the Company will be presenting data on the effects of its GalNAc-siRNA, AB-729, in chronic hepatitis B patients on nucleoside analogue therapy at The American Association for the Study of Liver Diseases – The Liver Meeting® 2021 – The Digital Experience™, taking place from November 12-15, 2021.

• Arbutus to Report Third Quarter 2021 Financial Results and Provide Corporate Update

  10/21/2021

  Arbutus Biopharma Corporation today announced that it has scheduled its third quarter 2021 financial results and corporate update for Thursday, November 4, 2021.

• Arbutus to Participate in October 2021 Investor Conferences

  9/28/2021

  Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company primarily focused on discovering, developing and commercializing a cure for people with chronic hepatitis B virus infection, as well as therapies to treat coronaviruses, announced that the Company will participate in the following October investor conferences:

• Arbutus Appoints Lisa M. Caperelli as Vice President, Investor Relations

  9/21/2021

  Arbutus Biopharma Corporation announced the Company has appointed Lisa M. Caperelli to the newly created position of Vice President of Investor Relations, leading investor relations strategy and communications activities, reporting to David Hastings, Arbutus’ Chief Financial Officer.

• Arbutus to Participate in Upcoming Investor Conferences

  9/7/2021

  Arbutus Biopharma Corporation today announced that the Company will participate in the following upcoming virtual investor conferences: H.C. Wainwright 23rd Annual Global Investment Conference September 13-15, 2021.

• Arbutus Reports Second Quarter 2021 Financial Results and Provides Corporate Update

  8/5/2021

  Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company primarily focused on discovering, developing and commercializing a cure for people with chronic hepatitis B virus infection, as well as therapies to treat coronaviruses, reports its second quarter 2021 financial results and provides a corporate update.

• Arbutus to Present at Wedbush PacGrow Healthcare Virtual Conference - Aug 03, 2021

  8/3/2021

  Arbutus Biopharma Corporation announced that the Company will participate in a fireside chat at the Wedbush PacGrow Healthcare Virtual Conference on Tuesday, August 10, 2021 at 4:05 PM ET.

• Arbutus to Report Second Quarter 2021 Financial Results and Provide Corporate Update

  7/29/2021

  Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company primarily focused on discovering, developing and commercializing a cure for people with chronic hepatitis B virus infection, as well as therapies to treat coronaviruses, announced that it has scheduled its second quarter 2021 financial results and corporate update for Thursday, August 5, 2021.

• Arbutus Receives Authorization to Proceed with an Investigational New Drug Application (IND) for AB-729, its Proprietary Subcutaneously-Delivered RNAi Agent

  7/7/2021

  Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company primarily focused on developing a cure for people with chronic hepatitis B virus infection, as well as therapies to treat coronaviruses, announced it has received authorization from the U.S. Food and Drug Administration to proceed with its Investigational New Drug application for AB-729 in a Phase 2a clinical trial.

• Arbutus Biopharma and Vaccitech Announce Clinical Trial Collaboration Agreement to Evaluate RNAi Therapeutic, AB-729, in Combination with Immunotherapeutic, VTP-300, in Subjects with Chronic Hepatitis B Virus Infection

  7/6/2021

  Arbutus Biopharma Corporation and Vaccitech plc announced that the companies have entered into a clinical trial collaboration agreement to evaluate an innovative therapeutic combination for the treatment of subjects with chronic hepatitis B virus infection who are already receiving standard-of-care nucleoside reverse transcriptase inhibitor therapy.

• 

  Biopharmas Ink Strategic Partnerships for Research, Treating Major Diseases

  6/29/2021

  ​Three partnerships were signed today between biopharmaceutical and therapeutics companies in a bid to develop treatment for major diseases with high mortality rates. 

• Arbutus Biopharma and Antios Therapeutics Announce Clinical Collaboration Agreement to Evaluate AB-729 in Combination with ATI-2173 in Subjects with Chronic Hepatitis B Virus Infection

  6/29/2021

  Antios Therapeutics, Inc. and Arbutus Biopharma Corporation announced that the companies have entered into a clinical collaboration agreement to evaluate a triple combination of Arbutus’ proprietary GalNAc delivered RNAi therapeutic, AB-729, Antios’ proprietary active site polymerase inhibitor nucleotide, ATI-2173, and Viread, for the treatment of subjects with chronic hepatitis B virus infection.

• Arbutus Announces New Data on AB-729 and AB-836 Programs with Presentation of Five Abstracts at the EASL International Liver Congress™ 2021 - All Selected for Best of ILC™

  6/26/2021

  Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company primarily focused on developing a cure for people with chronic hepatitis B virus infection, as well as therapies to treat coronaviruses, announced the presentation of five abstracts at the European Association for the Study of the Liver International Liver CongressTM.

• Arbutus Announces Multiple Abstracts Accepted for Oral and Poster Presentations at the EASL 2021 International Liver Congress in June

  6/2/2021

  Conference Call and Webcast to discuss the new data being presented at EASL  scheduled for 8:00 AM ET, Monday, June 28, 2021

• Arbutus to Participate in Upcoming Investor Conferences - May 26, 2021

  5/26/2021

  Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company primarily focused on developing a cure for people with chronic hepatitis B virus infection, as well as therapies to treat coronaviruses, announced that the Company will participate in the following upcoming investor conferences

• Arbutus Reports First Quarter 2021 Financial Results and Provides Corporate Update

  5/5/2021

  AB-729, Arbutus’ proprietary subcutaneously delivered RNAi agent, continues to demonstrate robust and continuous declines in hepatitis B surface antigen (HBsAg) in subjects with chronic hepatitis B (HBV) with favorable safety and tolerability data Additional data from the ongoing Phase 1a/1b clinical trial of AB-729, including 60 mg multi-dose data (dosing interval every 4 and 8 weeks) and 90 mg multi-dose data (dosing interval every 8 weeks), expected in 2Q/2021